HealthCor Management’s Acadia Pharmaceuticals ACAD Stock Holding History

HealthCor Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-900,490	Closed	-$23.2M	–	74
2021 Q1	$23.2M	Buy	+900,490	New	+$39.6M	0.82%	39
2020 Q3	–	Sell	-1,025,000	Closed	-$49.7M	–	42
2020 Q2	$49.7M	Sell	1,025,000 -1,205,474	-54%	-$57.9M	2.08%	24
2020 Q1	$94.2M	Buy	+2,230,474	New	+$91.9M	4.03%	8
2019 Q3	–	Sell	-119,484	Closed	-$3.19M	–	53
2019 Q2	$3.19M	Buy	+119,484	New	+$3.05M	0.12%	50
2018 Q2	–	Sell	-1,378,000	Closed	-$31M	–	53
2018 Q1	$31M	Buy	+1,378,000	New	+$38.2M	1.05%	32
2016 Q2	–	Sell	-200,000	Closed	-$5.59M	–	44
2016 Q1	$5.59M	Sell	200,000 -386,564	-66%	-$8.43M	0.32%	36
2015 Q4	$20.9M	Sell	586,564 -92,136	-14%	-$3.25M	1.27%	24
2015 Q3	$22.4M	Sell	678,700 -146,300	-18%	-$6.09M	1.26%	23
2015 Q2	$34.6M	Buy	825,000 +100,000	+14%	+$3.87M	1.74%	20
2015 Q1	$23.6M	Buy	+725,000	New	+$24.9M	1.13%	35
2014 Q3	–	Sell	-216,500	Closed	-$4.89M	–	50
2014 Q2	$4.89M	Sell	216,500 -483,500	-69%	-$10.1M	0.25%	43
2014 Q1	$17M	Buy	+700,000	New	+$17.7M	1.02%	27

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HealthCor Management's ACAD Position: Q2 2021 in Review

HealthCor Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 900,490 shares — an estimated $23.2M sold.

HealthCor Management first reported a position in ACAD in Q1 2014 and held it in 12 quarters. The position peaked at $94.2M in Q1 2020. 244 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

HealthCor Management reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
HealthCor Management sold 900,490 Acadia Pharmaceuticals shares in Q2 2021, an estimated $23.2M.
HealthCor Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 12 quarters.
HealthCor Management's Acadia Pharmaceuticals position peaked at $94.2M in Q1 2020.
244 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.